Can-Fite BioPharma (CANF) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CANF Can-Fite BioPharma

Watchlist

1.4800
+0.0400+2.78%

Close Dec 20 16:00 ET

1.4400
-0.0400-2.70%

Post 20:01 ET

9.02MMarket Cap-0.57P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Can-Fite Biopharma Has Received A Notice Of Allowance For A US Patent Titled "AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT (FOR THE TREATMENT OF OBESITY)"
BenzingaDec 12 15:58 ET
Bears Are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
Zacks Dec 9 09:05 ET
Can-Fite Biopharma Price Target Maintained With a $10.00/Share by D. Boral Capital
Dow JonesDec 5 07:16 ET · Ratings
Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital
Dow JonesDec 5 07:16 ET · Ratings
Can-Fite BioPharma Reports 8-Year Survival With Namodenoson in Liver Cancer Patient and Announces Phase III Study Enrollment
Quiver QuantitativeDec 4 07:12 ET
8 Years Survival With Complete Cure for a Patient With Advanced Liver Cancer Being Treated With Can-Fite's Namodenoson Drug
GlobeNewswireDec 4 07:00 ET

Comments

Airbender

Dec 18 14:54

Wondering if this FDA approved stock will ever come to life…

$Can-Fite BioPharma (CANF.US)$

wwwarrior

Dec 13 10:02

$Can-Fite BioPharma (CANF.US)$ Geez, trying to get an order to fill at the supposed ask price is next to impossible for me right now, it will only let me fill almost .03 above ask hahaha

learning-it

Dec 12 15:33

$Can-Fite BioPharma (CANF.US)$
Can-Fite Biopharma Has Received A Notice Of Allowance For A US Patent Titled "AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT (FOR THE TREATMENT OF OBESITY)"